bioMérieux, Marcy l'Étoile, France.
bioMérieux Inc., Salt Lake City, Utah, USA.
Microbiol Spectr. 2022 Oct 26;10(5):e0236822. doi: 10.1128/spectrum.02368-22. Epub 2022 Sep 26.
Respiratory tract infection (RTI) is a common cause of visits to the hospital emergency department. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), nonpharmaceutical intervention has influenced the rates of circulating respiratory viruses. In this study, we sought to detect RTI etiological agents other than SARS-CoV-2 in emergency department patients from 13 countries in Europe, the Middle East, and Africa from December 2020 to March 2021. We sought to measure the impact of patient characteristics and national-level behavioral restrictions on the positivity rate for RTI agents. Using the BioFire Respiratory Panel 2.0 Plus, 1,334 nasopharyngeal swabs from patients with RTI symptoms who were negative for SARS-CoV-2 were tested. The rate of positivity for viral or bacterial targets was 36.3%. Regarding viral targets, human rhinovirus or enterovirus was the most prevalent (56.5%), followed by human coronaviruses (11.0%) and adenoviruses (9.9%). Interestingly, age stratification showed that the positivity rate was significantly higher in the children's group than in the adults' group (68.8% versus 28.2%). In particular, human rhinovirus or enterovirus, the respiratory syncytial virus, and other viruses, such as the human metapneumovirus, were more frequently detected in children than in adults. A logistic regression model was also used to determine an association between the rate of positivity for viral agents with each country's behavioral restrictions or with patients' age and sex. Despite the impact of behavioral restrictions, various RTI pathogens were actively circulating, particularly in children, across the 13 countries. As SARS-CoV-2 has dominated the diagnostic strategies for RTIs during the current COVID-19 pandemic situation, our data provide evidence that a variety of RTI pathogens may be circulating in each of the 13 countries included in the study. It is now plausible that the COVID-19 pandemic will one day move forward to endemicity. Our study illustrates the potential utility of detecting respiratory pathogens other than SARS-CoV-2 in patients who are admitted to the emergency department for RTI symptoms. Knowing if a symptomatic patient is solely infected by an RTI pathogen or coinfected with SARS-CoV-2 may drive timely and appropriate clinical decision-making, especially in the emergency department setting.
呼吸道感染(RTI)是急诊科就诊的常见原因。在当前由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)大流行期间,非药物干预措施影响了循环呼吸道病毒的发生率。在这项研究中,我们试图在 2020 年 12 月至 2021 年 3 月期间从欧洲、中东和非洲的 13 个国家检测急诊科患者中除 SARS-CoV-2 以外的 RTI 病原体。我们试图衡量患者特征和国家层面的行为限制对 RTI 病原体阳性率的影响。使用生物火呼吸道 2.0 加检测试剂盒,对 1334 名鼻咽拭子进行了检测,这些拭子来自 COVID-19 检测阴性的有 RTI 症状的患者。病毒或细菌检测目标的阳性率为 36.3%。在病毒检测目标方面,人鼻病毒或肠道病毒最为常见(56.5%),其次是人类冠状病毒(11.0%)和腺病毒(9.9%)。有趣的是,年龄分层显示,儿童组的阳性率明显高于成年组(68.8%比 28.2%)。特别是,人鼻病毒或肠道病毒、呼吸道合胞病毒和其他病毒,如人类偏肺病毒,在儿童中的检出率高于成人。还使用逻辑回归模型来确定病毒检测阳性率与每个国家的行为限制或与患者年龄和性别之间的关联。尽管行为限制产生了影响,但各种 RTI 病原体仍在 13 个国家积极传播,尤其是在儿童中。由于 SARS-CoV-2 在当前 COVID-19 大流行情况下主导了 RTIs 的诊断策略,我们的数据提供了证据,表明在研究中包括的 13 个国家中的每一个国家都可能有多种 RTI 病原体在传播。目前看来,COVID-19 大流行将有一天会进入地方性流行阶段。我们的研究说明了在因 RTI 症状而入住急诊科的患者中检测 SARS-CoV-2 以外的呼吸道病原体的潜在效用。了解有症状的患者是否仅感染 RTI 病原体或与 SARS-CoV-2 共同感染,可能会推动及时和适当的临床决策,尤其是在急诊科环境中。